ReviewCNS drugs2011
The role of antipsychotics in smoking and smoking cessation.
Review in CNS drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The effect of nicotine dependence on psychopathology in patients with schizophrenia.BioMed research international · 2015Trial
- Nicotine Misuse and Treatment of Schizophrenia Exacerbations in Men: An Observational Study in Poland.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Association between cumulative exposure periods of flupentixol or any antipsychotics and risk of lung cancer.Communications medicine · 2023Article
- Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study.Frontiers in psychiatry · 2023Article
- Age-specific impacts of nicotine and withdrawal on hippocampal neuregulin signalling.The European journal of neuroscience · 2022Article
- Feasibility of a Consumer Centred Tobacco Management intervention in Community Mental Health Services in Australia.Community mental health journal · 2020Article
- Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort.European archives of psychiatry and clinical neuroscience · 2019Article
- Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset.European archives of psychiatry and clinical neuroscience · 2017Article
- Smoking in schizophrenic patients: A critique of the self-medication hypothesis.World journal of psychiatry · 2015Review
- Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders.International review of neurobiology · 2015Review
- Examination of the role of dopamine D₂ and adrenergic α₂ receptors in resurgence of food seeking.Behavioural brain research · 2014Article
- Effects of intravenous nicotine on prepulse inhibition in smokers and non-smokers: relationship with familial smoking.Psychopharmacology · 2013Article
- The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Review
- Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.Frontiers in pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Persons with severe and persistent mental illnesses, e.g. schizophrenia spectrum disorders and bipolar disorder, smoke at a much higher rate than the general population. Treatment options for schizophrenia spectrum disorders and bipolar disorder often include the first-generation (typical) and second-generation (atypical) antipsychotics, which have been shown to be effective in treating both psychotic and mood symptoms. This article reviews studies examining the relationship between antipsychotic medication and cigarette smoking. These studies suggest that in persons with schizophrenia and schizoaffective disorder, typical antipsychotics may increase basal smoking and decrease people's ability to stop smoking, whereas atypical antipsychotics decrease basal smoking and promote smoking cessation. However, we found that the data available were generally of moderate quality and from small studies, and that there were conflicting findings. The review also critically assesses a number of potential mechanisms for this effect: the use of smoking as a form of self-medication for the side effects of antipsychotics, the effect of antipsychotics on smoking-related cues and the effect of antipsychotics on the appreciation of the economic cost of smoking behaviour. Gaps in the research are noted and recommendations for further study are included. More study of this important issue is needed to clarify the effect of antipsychotics on smoking behaviours.
Indexed as
Identifiers
21425883What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.